SplitApr 21, 2026, 08:31 AM
Plus Therapeutics Regains Nasdaq Compliance After Reverse Split
AI Summary
Plus Therapeutics, Inc. announced it has regained compliance with The Nasdaq Capital Market's minimum bid price requirement. The company received written notice from Nasdaq on April 20, 2026, confirming its compliance. This achievement follows the implementation of a one-for-twenty-five reverse stock split, which became effective on April 2, 2026.
Key Highlights
- Regained compliance with Nasdaq minimum bid price requirement.
- Notification received on April 20, 2026.
- Compliance followed a one-for-twenty-five reverse stock split.
- Reverse split became effective on April 2, 2026.